Keywords
Public health crisis
Pharmaceutical patents
TRIPS agreement
Submitted : 2025-01-08
Accepted : 2025-01-23
Published : 2025-02-07
Abstract
Ensuring the supply of medicines is extremely important during major public health crises. Implementing compulsory licensing of pharmaceutical patents is a means to guarantee an adequate and effective supply of medicines. Although China’s current compulsory licensing system for pharmaceutical patents has clear legal provisions, there are many issues. To ensure the effective implementation of the system, it is necessary to relax the qualifications of the applicants, add new objects of compulsory licensing, clarify the reasons for application, and explore more efficient application procedures.
References
Li CF, 2019, Defects and Improvement Paths of China’s Pharmaceutical Patent Compulsory Licensing System. Administrative and Law, 2019(2): 95–105.
Li CF, 2018, International Practice of Pharmaceutical Patent Compulsory Licensing System under the TRIPS Agreement and China’s Reform Path. Innovation and Technology, 2018(10): 76–79.
Liu YH, 2010, On the Patent Compulsory Licensing System — A Review of the Relevant Provisions of the Third Revision of the Patent Law. Hebei Law Science, 2010(4): 244.
Wang JT, 2021, Defects and Reform Ideas of China’s Pharmaceutical Patent Compulsory Licensing System. Journal of Qingdao University of Science and Technology (Social Science Edition), 2021(4): 65.
Liu LC, Qi S, 2020, Research on the Object of Pharmaceutical Patent Compulsory Licensing under Sudden Epidemics. Electronic Intellectual Property, 2020(10): 11.
Xiao SG, 2020, Research on Legal Issues of Trademark Use Restrictions from the Perspective of Protecting Public Health. Wuhan University Press, Wuhan.